<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893293</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20253(osteonecrosis)</org_study_id>
    <secondary_id>PEDSBONE0006</secondary_id>
    <nct_id>NCT02893293</nct_id>
  </id_info>
  <brief_title>Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI</brief_title>
  <acronym>Osteonecrosis</acronym>
  <official_title>Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the project is to evaluate osteonecrosis before and after decompression surgery&#xD;
      with ferumoxytol-enhanced MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the project is to evaluate osteonecrosis before and after decompression surgery&#xD;
      with ferumoxytol-enhanced MRI.&#xD;
&#xD;
      The investigators approach relies on the FDA-approved iron supplement ferumoxytol (Feraheme),&#xD;
      which is used off label as a contrast agent for MRI. Ferumoxytol is composed of iron oxide&#xD;
      nanoparticles, which provide a strong T1- and T2-signal on magnetic resonance (MR) images and&#xD;
      are taken up by cells in bone marrow.&#xD;
&#xD;
      20 patients will undergo MRI before and after decompression surgery and transplantation of&#xD;
      bone marrow derived cells. 10 patients will receive a single intravenous injection of&#xD;
      ferumoxytol prior to their surgery. 10 additional patients will serve as untreated controls.&#xD;
      The investigators hypothesize that MR images after intravenous injection of ferumoxytol will&#xD;
      improve lesion detection and allow to track transplanted bone marrow cells. MR imaging&#xD;
      findings will be correlated with clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of treatment response to decompression surgery and stem cell transplant</measure>
    <time_frame>one year</time_frame>
    <description>Evaluation of progression of osteonecrosis via scale 1-4, bone marrow edema, collapse of subchondral fractures.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Osteonecrosis</condition>
  <arm_group>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ferumoxytol enhanced MRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferumoxytol-enhanced magnetic resonance imaging</intervention_name>
    <description>Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant</description>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magentic Resonance Imaging</intervention_name>
    <description>Both arms will receive MRI</description>
    <arm_group_label>Ferumoxytol-enhanced MRI</arm_group_label>
    <arm_group_label>Non-ferumoxytol enhanced MRI</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteonecrosis&#xD;
&#xD;
          -  planned decompression surgery with autologous stem cell transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for magnetic resonance imaging&#xD;
&#xD;
          -  Hemosiderosis/hemochromatosis ( patients can still be included in the non-ferumoxytol&#xD;
             arm)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heike Daldrup-Link, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://daldrup-link-lab.stanford.edu/</url>
    <description>Pediatric Molecular Imaging Program</description>
  </link>
  <reference>
    <citation>Muehe AM, Feng D, von Eyben R, Luna-Fineman S, Link MP, Muthig T, Huddleston AE, Neuwelt EA, Daldrup-Link HE. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Invest Radiol. 2016 Apr;51(4):221-227. doi: 10.1097/RLI.0000000000000230.</citation>
    <PMID>26656202</PMID>
  </reference>
  <reference>
    <citation>Nejadnik H, Lenkov O, Gassert F, Fretwell D, Lam I, Daldrup-Link HE. Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects. Sci Rep. 2016 May 13;6:25897. doi: 10.1038/srep25897.</citation>
    <PMID>27174199</PMID>
  </reference>
  <results_reference>
    <citation>Theruvath AJ, Nejadnik H, Muehe AM, Gassert F, Lacayo NJ, Goodman SB, Daldrup-Link HE. Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients. Clin Cancer Res. 2018 Dec 15;24(24):6223-6229. doi: 10.1158/1078-0432.CCR-18-1687. Epub 2018 Sep 17.</citation>
    <PMID>30224340</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Heike E Daldrup-Link</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

